Centre Hospitalier Universitaire de Sherbrooke

Testosterone Recovery After ADT Shows 46% Lower Mortality Risk in High-Risk Prostate Cancer Study

- Long-term data from the phase III PCS4 trial reveals patients who recovered normal testosterone levels after androgen-deprivation therapy showed a 46% reduction in mortality risk compared to non-recoverers. - Patients receiving 18 months of ADT demonstrated higher testosterone recovery rates (57%) compared to those on 36-month treatment (44.3%), though therapy duration did not directly impact overall survival. - The study, spanning over 17 years with 515 patients, found testosterone recovery to be an independent predictor of overall survival, regardless of recovery timing.